0001877104-21-000001.txt : 20210806 0001877104-21-000001.hdr.sgml : 20210806 20210806151322 ACCESSION NUMBER: 0001877104-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210806 DATE AS OF CHANGE: 20210806 EFFECTIVENESS DATE: 20210806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioRegenx Inc. CENTRAL INDEX KEY: 0001877104 IRS NUMBER: 861820793 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-409141 FILM NUMBER: 211152568 BUSINESS ADDRESS: STREET 1: 7407 ZIEGLER ROAD CITY: CHATTANOOGA STATE: TN ZIP: 37421 BUSINESS PHONE: 423-580-7722 MAIL ADDRESS: STREET 1: 7407 ZIEGLER ROAD CITY: CHATTANOOGA STATE: TN ZIP: 37421 D 1 primary_doc.xml X0708 D LIVE 0001877104 BioRegenx Inc. 7407 ZIEGLER ROAD CHATTANOOGA TN TENNESSEE 37421 423-580-7722 NEVADA None None Corporation true 2021 William Resides 7407 Ziegler Road Chattanooga TN TENNESSEE 37421 Executive Officer Director Promoter CEO/Interim CFO/Director Robert Long 7 S. Lone Peak Drive Alpine UT UTAH 84004 Executive Officer Director Promoter Chairman of the Board/Chief Operating Officer/Director Robert Doran 7407 Ziegler Road Chattanooga TN TENNESSEE 37421 Executive Officer Director Promoter Executive Vice President/Director Hans Vink Groot Haasdal 3 6333 AV Schimmert P7 NETHERLANDS 6333 AV Executive Officer Director Promoter Chief Science Officer/Director Joseph Simmons Bird, Jr. 7407 Ziegler Road Chatanooga TN TENNESSEE 37421 Executive Officer Director Promoter Chief Medical Officer/Treasurer/Director Gary Dale Hennerberg 5501 Willow Lane Colleyville TX TEXAS 76034 Executive Officer Director Promoter Chief Marketing Officer/Operations/Secretary/Director Biotechnology $5,000,001 - $25,000,000 06b false 2021-07-20 false true false 0 3000000 615456 2384544 true 11 23 0 0 945935 true From the funds used to purchase GlycoCheck, Bob Long will receive $67,968 from the sale of his GlycoCheck shares and $436,600 for management fees. Hans Vine will receive $90,624 from the sale of his GlycoCheck shares and $350,743 for management fees. false BioRegenx Inc. William Resides William Resides CEO 2021-08-06